Literature DB >> 29477264

Patient Knowledge Regarding Colorectal Cancer Risk, Opinion of Screening, and Preferences for a Screening Test.

Courtney C Moreno1, Thomas Jarrett2, Brianna L Vey3, Pardeep K Mittal4, Elizabeth A Krupinski4, David L Roberts2.   

Abstract

AIMS: To assess patient knowledge about colorectal cancer incidence and prognosis as well as willingness to undergo screening with various tests (eg, optical colonoscopy, stool-based tests, computed tomographic colonography (CTC)).
MATERIALS AND METHODS: A survey was administered to consecutive patients of a general academic-based internal medicine clinic.
RESULTS: Survey response rate was 86.3%. A majority of respondents (55%) reported being aware of general information about colorectal cancer, and 99% indicated a belief that colorectal cancer screening was a good idea. A majority of respondents (73%) were willing to undergo optical colonoscopy, and some were willing to undergo stool-based tests (48%), or CT colonography CTC (40%). A majority reported being more willing to undergo a colorectal cancer screening test if the test did not involve radiation (86%), did not involve insertion of a tube or device into the rectum (78%), did not involve a pre-proceduralpreprocedural bowel cleansing regimen (73%), or did not involve sedation (60%).
CONCLUSION: Improved patient education about the negligible radiation risk associated with CTC or development of a non-invasive imaging test that did not involve a preprocedural bowel cleansing regimen may increase rates of colorectal cancer screening.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29477264     DOI: 10.1067/j.cpradiol.2017.12.011

Source DB:  PubMed          Journal:  Curr Probl Diagn Radiol        ISSN: 0363-0188


  1 in total

1.  Improving Colon Cancer Prevention in Poland. A Long Way Off.

Authors:  Karolina Obiała; Justyna Obiała; Krzysztof Jeziorski; Jakub Owoc; Małgorzata Mańczak; Robert Olszewski
Journal:  J Cancer Educ       Date:  2022-06       Impact factor: 1.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.